Celleo Biotech Pty Ltd

Celleo Biotech Pty Ltd, based in Australia, specializes in revolutionizing the manufacturing processes of cell therapies through advanced Intelligent Production Systems. Founded in 2022 in Melbourne, Australia, Celleo Biotech Pty Ltd focuses on developing innovative production systems for cell therapies. The company has completed 1 deal, raising AUD 5 million in a funding round on June 19, 2025, with a current valuation of AUD 25 million. Celleo specializes in the development of Intelligent Production Systems for Cell Therapy™, which aim to enhance manufacturing processes in the biotherapeutics industry.

Their core offerings include GMP production systems tailored for various business models, developed in collaboration with leading biotherapeutics companies and major medical centers. Key products include the Larkem V40 system, recently shipped to a CAR-T cell therapy producer in the United States for technical evaluation. Celleo generates revenue through B2B transactions with biopharma companies and CDMOs within the cell therapy sector. Revenue is primarily derived from the sale and leasing of Intelligent Production Systems, including ongoing support and maintenance agreements to ensure operational efficiency.

This structure promotes long-term client relationships in the biotherapeutics field. In June 2025, Celleo Biotech Pty Ltd raised AUD 5 million in venture funding, which will be directed towards developing automated systems for manufacturing cancer cell therapies. The company aims to expand its market presence into North America, Europe, and Asia-Pacific, enhancing personalized healthcare through its advanced offerings.